Recruiting

Observational Study

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07215611

Conditions

Bone Sarcomas

Financial Toxicity

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

data collection

Study Details

Brief summary:

To learn about the financial stress patients undergoing surgery to treat orthopedic cancer experience because of the costs of cancer care, and to learn about the effects of financial stress on participants quality of life.

Conditions

Bone Sarcomas

Financial Toxicity

Study ID

NCT07215611

Start date

Sep 2, 2025

Status verified date

Apr, 2026

Completion date

Oct 2, 2030

Anticipated

Primary completion date

Oct 2, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants who are seen preoperatively at our institution before surgery for primary malignant bone tumor or primary malignant soft tissue tumor will be identified.
  • Adult orthopedic oncology patients. Stratified by diagnosis of primary malignant bone tumor and primary malignant soft tissue tumor.

Exclusion Criteria

• Non-English subjects will not be recruited. Subjects are required to be able to read/write in English.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Interventions

data collection

data collection from electronic health records

Primary outcome measure

  • Questionnaires [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts and Locations

Central contacts

Shalin S Patel, MD

713-792-6268sspatel@mdanderson.org

Locations

MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Shalin S Patel, MD

713-792-6268sspatel@mdanderson.org

Principal Investigator:

Shalin S Patel, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Apr 30, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-04-30.